NET CONNECT’s Post

View organization page for NET CONNECT, graphic

162 followers

New insights from mid-treatment response to 177-Lutetium Dotatate in Advanced NETs❗ A study of 51 patients treated with 177-Lutetium Dotatate revealed: 41% achieved partial response (PR), 45% stable disease (SD), and 6% progressive disease (PD). PR was notably achieved after the second cycle in 70.4% cases, with mid-treatment PR predicting continued success (OR 20.9, p = 0.002). Significant tumour reduction seen in pancreatic NETs highlights PRRT's potential in managing challenging cases. https://ow.ly/SzJe50Sssba #NeuroendocrineTumors #PRRT

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics